Interestingly, NTN1 positivity was associated with poor glioma-specific survival (hazard ratio [HR] = 1.73, 95% confidence interval [95% CI] = 1.11 to 2.71; p = 0.015) (Fig. 1a) and with shorter recurrence-free survival time (HR = 1.62, 95% CI = 1.04 to 2.53; p < 0.001) (Fig. 1b). This evidence concerns the gene NTN1 and central nervous system cancer.